Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund

This article was originally published in Start Up

Executive Summary

The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.

You may also be interested in...



Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.

Lotus Tissue Repair Scores $26 Million in Series A Round

Rare disease start-up scores Series A financing and technology patents to develop a treatment for a deadly genetic disorder.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel